Purpose: Upper-extremity soft-tissue sarcomas are a rare disease with unclear epidemiology and evolving treatment strategies. Our purpose is to evaluate the incidence of upper-extremity softtissue sarcomas and the use of adjuvant radiotherapy in this patient population. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) database, a national population-based database, we identified all cases of primary upper-extremity sarcoma reported to the 9 national SEER registries in the Untied States from 1973 to 1998. Results: Of the 1,286 upper-extremity soft-tissue sarcomas the average incidence rate is 2.2 cases/million/y, which has not changed significantly from 1973 to 1998. Caucasians' average incidence rate is significantly higher than African Americans' (incidence rate ratio [IRR] ϭ 1.3, p ϭ .02); and men are at a significantly higher risk compared with women (IRR ϭ 1.3, p Ͻ .01). The use of adjuvant radiotherapy has increased significantly from 17% in 1973 to 47% in 1998 (p Ͻ .01). African-Americans, compared with Caucasians, are significantly less likely to receive adjuvant radiotherapy (odds ratio [OR] ϭ .5, p ϭ .01).
Soft-tissue sarcomas of the upper extremity are rare, accounting for approximately 1% of all malignancies, but are associated with considerable morbidity and mortality. 1 Because of its rarity our knowledge of the disease is limited to case series in single centers that generally involve 40 or fewer patients. [2] [3] [4] [5] [6] [7] Although Sweden has published one of the largest reviews of upper-extremity sarcoma involving 108 sarcoma patients, 8 data on the US population are limited. Evaluating trends in cancer incidence and treatment are important. Currently most of the attention directed toward the incidence of sarcoma has focused on the Kaposi subtype because of its association with the human immunodeficiency virus. The epidemiology of the remaining sarcoma subtypes remains relatively unexplored.
Although treatment modalities in health care progress over time improvements in socioeconomic and sociodemographic barriers to health care are more static. Epidemiologic studies in the 1960s un-covered the disturbing relationship between low socioeconomic status and poor health status. 9 Disparities in health care based on sex and race also exist in our current health care system with women and African Americans often receiving less aggressive care. 10 -15 The increasing popularity of adjuvant radiotherapy highlights the need to evaluate which segments of the sarcoma population are receiving this treatment.
In this national population database analysis we evaluated trends in the incidence of primary upperextremity soft-tissue sarcomas for a 26-year period from 1973 to 1998, focusing on the association between demographic factors and the different subtypes of sarcoma. Cancer can differentially target individuals by age, race, and sex, which are important data for the clinical detection of the disease. In addition we evaluated potential sociodemographic inequalities in the use of adjuvant radiotherapy for this population.
Materials and Methods

Database Characteristics
The Surveillance, Epidemiology, and End Results (SEER) program was created in 1973 by the National Cancer Institute and is one of the most comprehensive sources of information on cancer incidence in the United States. The SEER program collects cancer data from 11 population-based registries covering approximately 14% of the US population. Data on more than 3 million cancer cases are included within the database and approximately 170,000 new cases are accessioned each year. 16 SEER incorporates epidemiologically distinct population subgroups into the sample population focusing on race, income, and education parameters, which enhance the generalizability of the sample to the US population. 16 For example SEER has registries in Hawaii and New Mexico to capture the Asian and Hispanic populations. The sociodemographic characteristics of the SEER and the US populations are as follows: 12% of SEER versus 13% of the US population is below the poverty level; 78% of SEER versus 75% of the US population has at least a high school degree; 89% of SEER versus 75% of the US population is from an urban population. 16 The database has provided insightful data used by researchers studying many types of cancer such as cervical, lung, breast, prostate, and colorectal carcinoma and sarcomas. 11, 12, [17] [18] [19] [20] [21] In addition the database provides information for the following publications and reports: Annual Report to the Nation, which is an update on cancer incidence and death rates in the United States; SEER Cancer Statistics Review, which is used by the National Cancer Institute to monitor population subgroups requiring cancer control efforts; and Racial/ Ethnic Patterns of Cancer in the United States, 1988 States, -1992 . 16 Although the SEER database includes 11 national registries, 2 of the registries were established recently and have not collected data for the entire study period. Therefore we included the 9 registries established since 1973: San Francisco, Connecticut, Metro Detroit, Hawaii, Iowa, New Mexico, Seattle (Puget Sound), Utah, and Metro Atlanta. Patients from all types of health care systems and insurance carriers are included. The SEER database is available publicly; however, we had no involvement in the design of the database or the collection of data.
Study Population
From the SEER public-use data file we obtained data on all cases of primary soft-tissue sarcoma affecting one or both upper extremities from 1973 to 1998 that were reported to one of the 9 national SEER registries. Our target population, men and women with soft-tissue sarcoma, was identified by using the International Classification of Diseases for Oncology . We excluded from our study population Kaposi's sarcoma because of the increased incidence of the disease related to the human immunodeficiency virus.
Data Analysis
The average incidence of disease for the 26-year study period was calculated by dividing the total number of new sarcoma cases each year by the population included in the 9 registries. To test for significant trends in the incidence of sarcoma from 1973 to 1998 we performed a nonparametric test for trends. As a way to compare incidence rates between subgroups, such as between men and women, incidence rate ratios (IRRs) were calculated and the between-subgroup rate comparisons were based on binomial probabilities. We used a logistic regression model to analyze the predictors of adjuvant radiotherapy in this population including preoperative and postoperative radiotherapy. In this model the primary dependent variable was receipt of adjuvant radiotherapy (yes/no). The effects of patient age at diagnosis, sex, race, marital status, geographic treatment location, and year of diagnosis on the dependent variable were evaluated while controlling for the stage of the disease. The odds ratios (ORs) were calculated from this model as a measure of the strength of the association between a predictor variable and the receipt of radiotherapy.
We dichotomized radiotherapy by combining beam, radioactive implants, radioisotopes, and unspecified radiotherapy into a general radiotherapy category, and we dichotomized the marital status variable by combining the single, divorced, separated, and widowed cases into an unmarried category. Because the race category definition for Asians and Hispanics was not consistent over the SEER data collection periods race was evaluated only as Caucasian versus African American. Dummy variables were created for the categoric variables with men, Caucasians, and married individuals chosen as reference groups because the majority of upper-extremity sarcoma cases were in these categories. Eight dummy variables were created for the 9 registries with San Francisco, which had the most representative racial distribution, as the registry reference group. We also had no a priori reason to expect any particular registry to display significant variations in practice compared with the other registries. We also did not have a hypothesis of interaction between predictors and thus interaction was not examined. All analyses were performed with a statistical software package (STATA version 6.0; College Station, TX) and statistical significance was set at p Յ .05 (2-tailed).
Results
From 1973 to 1998 the 9 SEER registries had data on 1,286 cases of upper-extremity sarcoma. Table 1 summarizes the sociodemographic characteristics of the study population. The majority of individuals were Caucasian (83.7%) and 55.3% were men. Localized disease as opposed to regional or distant was the predominant stage (70.7%), and 36.0% of all sarcoma cases received adjuvant radiotherapy. The mean age at diagnosis was 54.5 years; however, the sarcoma subtypes differentially target individuals by age (Fig. 1) . For example the median age of individuals with epithelioid, clear cell, and synovial sarcomas ranged from 25 to 34 years, which is younger than the median age of individuals with angiosarcoma, MFH, and spindle cell sarcoma, ranging from 64 to 68 years.
The average incidence of sarcoma for each subtype over the 26-year period is displayed in Table 2 . The most common sarcoma of the upper extremity in the SEER database was MFH. Overall for all sarcoma subtypes the incidence did not change significantly from 1973 to 1998 (p ϭ .29) (Fig. 2) . For the individual subtypes, however, the incidence of MFH significantly increased (p Ͻ .01) and the incidence of fibrosarcoma and liposarcoma significantly decreased over the study period (p ϭ .02, p Ͻ .01, respectively).
The incidence rate comparisons of upper-extremity sarcoma between men and women are presented in Table 3 . For all types of sarcoma combined the incidence in men was significantly higher than in women (IRR ϭ 1.29, p Ͻ .01). For angiosarcoma, however, men were at significantly lower risk than women (IRR ϭ .5, p Ͻ .05). The sarcoma incidence rate comparisons by race are displayed in Table 4 . For all sarcoma subtypes combined Caucasians were at a significantly higher risk for the disease compared with African Americans (IRR ϭ 1.25, p ϭ .02). In particular Caucasians were more than twice at risk for leiomyosarcoma compared with African Americans (IRR ϭ 2.24, p ϭ .02). The logistic regression model predicting receipt of adjuvant radiotherapy for upper-extremity sarcoma is shown in Table 5 . The covariates that were controlled for in the regression were age, sex, race (African Americans vs Caucasians), marital status, SEER registry, stage of disease, and year at diagnosis. Race was a significant predictor of adjuvant radiotherapy. Controlling for the other covariates African Americans compared with Caucasians were significantly less likely to receive radiation (OR ϭ .54, p ϭ .02). Figure 3 displays the higher percentage of Caucasians compared with African Americans who received adjuvant radiotherapy for each stage of the disease. Because 10% of the sample was not staged we performed sensitivity analyses to ensure that a bias did not account for the significant race effect on the use of radiotherapy. Even among those who were not staged Caucasians were more likely to receive radiotherapy compared with African Americans (OR ϭ 1.12, p ϭ .02). It also should be noted that only 8.6% of the population were African Americans, which contributed to only 4 patients in the regional stage and 1 patient in the distant stage who received radiotherapy (Fig. 3) .
Other sociodemographic factors such as patient age at diagnosis, sex, and marital status were not significant predictors of radiotherapy. Geographic treatment location did significantly influence the use of radiotherapy. Compared with the San Francisco population individuals with upper-extremity sarcoma in most of the other registries were less likely to receive radiotherapy. For example while controlling for the other covariates an individual with an upperextremity sarcoma in Connecticut was approximately half as likely to receive adjuvant radiotherapy compared with an individual in San Francisco (OR ϭ .54, p ϭ .01). In addition the use of radiotherapy in this patient population has significantly increased over time (OR ϭ 1.06, p Ͻ .01), shown in Figure 4 .
Discussion
Soft-tissue sarcomas are associated with increased mortality and when located in the upper extremity the surgical extirpation can be functionally disabling. Although soft-tissue sarcomas have been related to environmental chemicals such as dioxin, vinyl chloride, and chlorphenols 1 our data suggest that the incidence of sarcomas located in the upper extremity is low (2.2 cases/million) and has not increased significantly over the past 3 decades. The significant decrease in the incidence of fibrosarcoma and liposarcoma and the increase in the incidence of MFH most likely represents a reporting bias owing to recent changes in the pathologic classification of sarcoma subtypes. 22 In addition these data represent the largest population-based study of upper-extremity sarcoma and correspond to Sweden's epidemiologic data, 8 which supports the validity of the SEER database.
In the SEER population the most common type of upper-extremity sarcoma is MFH, which is a similar finding in several smaller US and Swedish reports. 4, 8, [23] [24] [25] Most sarcoma incidence data vary on patient age at diagnosis. This variation likely reflects the most common sarcoma subtype of that institution. For example Brien et al 2 report a median age for sarcoma patients of 39 years but the most common tumor in their study was synovial sarcoma, which in the SEER population targets younger individuals compared with the other subtypes (Fig. 1 ). As seen with other types of cancer such as leukemia the SEER data suggest an age relationship with the subtype of sarcoma. In addition soft-tissue sarcomas of the upper extremity in general appear to differentially target men and Caucasians.
In our study the use of adjuvant radiotherapy for primary upper-extremity sarcomas was significantly increasing. This technique offers a more conservative surgical resection allowing for functional limb preservation. 3, 24, 26, 27 The use of adjuvant radiotherapy, however, was not distributed equally in this population because African Americans were much less likely to receive this treatment modality. These data support racial disparity research in the US health care system with African Americans receiving less medical care and less aggressive treatment interventions. 28 -31 The reason for the inequality is unclear. African Americans have had a distrust in the traditional health care system, which may influence their decision toward radiotherapy. 32 Access barriers, patient compliance, or provider bias also may play a role.
The SEER data suggest notable variations across the country in the use of adjuvant radiotherapy for soft-tissue sarcomas in the upper extremities. For example after controlling for the covariates an individual with an upper-extremity sarcoma in Iowa is less than half as likely to receive adjuvant radiotherapy compared with an individual in San Francisco. Provider bias, availability of radiotherapy, patient preference, and patient compliance need to be explored as potential sources for these variations in practice patterns. In addition outcome studies on the effects of radiotherapy focusing on function and survival are needed.
This study has several limitations. Although a national database aids in the generalizability of the study results the potential for unmeasured variables to confound the results is possible. Although we controlled for some sociodemographic variables and the stage of disease in the regression model variables such as income, urban versus rural location, and education may affect access to radiotherapy. In addition health status, tumor aggressiveness, and receipt of chemotherapy may effect the clinical decision to offer adjuvant radiotherapy. SEER also uses an inadequate staging system for this population instead of using the system devised by the Musculoskeletal Tumor Society that inhibits the use of survival analyses. 33, 34 In addition the race category was inconsistent for ethnically important groups such as Hispanics and Asians. SEER has one of the largest sarcoma databases, however, which provides important descriptive epidemiology for this population.
In summary, the incidence of primary soft-tissue sarcomas of the upper extremity has not significantly changed over the past 3 decades. Age, sex, and race, however, are important predictors of the disease. In addition the use of adjuvant radiotherapy for upperextremity sarcoma may be distributed unevenly with a lower use in African Americans compared with Caucasians. Future research is needed to determine if this disparity represents access to care limitations for African Americans, provider bias, patient preference, or patient compliance.
